1.2. Le VDAC come attori principali nella mediazione e nella regolazione delle funzioni mitocondriali con attività cellulari
1.2. VDACs as Main Players in Mediating and Regulating Mitochondrial Functions with Cellular Activities
LaThe posizione nell'OMM consente allelocation in the OMM allows the VDAC proteine VDAC di agire come punti di ancoraggio pes to act as anchor points for diversi insiemi die sets of molecole cheules that interagiscono con ict with mitocondri. In questo modo, i VDC sono in grado di mediare e regolare l'hondria. In this way, VDACs are able to mediate and regulate the integrazione delle funzionition of mitochondriali con le attività functions with cellulari activities.
L'intTherattoma VDAC comprendeinteractome includes proteine situates located in OMM, membranainner mitochondriale interna membrane (IMM), spazio iintermembranae space (IMS), ciytosol, reticolo endoendoplasmic reticulum, plasmatico, membrana plasmatica ee and nucleo che sono coinvolti nelus that are involved in metabolismo, apoptosi, trasduzione del segnales, signal transduction, protezione controction against ROS, legame abinding to RNA o DNA e altro ancorar DNA, and more.
La mMobilit
à della regioney of VDAC N-terminal
e α-elica è α-helix region is important
e per i for channel gating
dei canali, ma anche per le but also for intera
zioni con proteinections with both pro-apoptotic
he e and anti-apoptotic
he come proteins such as Bax, Bak
e, and Bcl-xL
[15][16][
17]15,16,17].
Il VDAC1
è coinvolto nel rilascio di fattoriis involved in the release of apoptotic
i localizzati nello spazio i factors located in the intermembran
a grazie alla sua capacità die space due to its ability of oligomeri
zzarsizing in dimer
i, esameri e strutture di ordine superiore, per formare un grande poro che consente il s, hexamers, and higher-order structures, to form a large pore that allows the passag
gio del citocromo c e del fattore di induzione dell'apoptosie of cytochrome c and apoptosis inducing factor (AIF)
al ci to the cytosol
e diand conse
guenza l'attivazione della morte cellulare programmata. Invecequently the activation of programmed cell death. Instead, VDAC2 fun
ziona come fattorections as anti-apoptotic
o ed è sovraregolato in diverse malattie factor and it is upregulated in several debilita
nti tra cui l'ting diseases including Alzheimer
e il cancro’s and cancer [18].
QueThis
ta proprietà è property is probab
ilmente dovuta alla capacità unica dily due to the unique ability of VDAC2
dito sequest
rare la proteinaer the pro-apoptotic
a Bak nell'OMM e mantenerla nello stato inattivo protein Bak in the OMM and maintain it in the inactive state [11].
VDAC1
modis
tra siti di legame, situati nella sua porzione ciplays binding sites, located in its cytosolic
a, per molti enzimi moiety, for many metabolic
i, come la gli enzymes, such as glyceralde
ide-3-fosfato deihyde 3-phosphate dehydrogenas
i, lae, creatin
chinasi, la glicerolo chinasi, la glucochinasi, la chinasi c-Raf e le kinase, glycerol kinase, glucokinase, c-Raf kinase, and hexokinase isoform
e e l'esochinasi (I es (I and II),
che necessitano di un accesso which need preferen
ziale all'ATPtial access to mitoc
hondrial
e ATP [19].
L'He
sochinasixokinase intera
gisce attraverso la sua sequenza idrofobicacts through its hydrophobic N-terminal
e con sequence with Glu
73 diof VDAC1,
un sito di legamea binding site localiz
zato su un lato della parete della canna, sepolto nell'ambiente idrofobo died on one side of the barrel wall, buried in the hydrophobic environment of OMM
[20].
ÈIt stato dimostrato che il trattamento dei mitocondri con dicicloesihas been demonstrated that treatment of mitochondria with dicyclohexylcarbodiimide (DCCD) in
ibisce l'hibits hexokinase–VDAC intera
zione esochinasi-VDAC a causa dellaction due to selective chemical modifica
chimica selettiva della gtion of Glu
73 [21].
IGl
u73 residu
oe di glu73is also è ancthe
il sito di legame per le binding site for ceramid
i, lipidi oncosoes, tumor suppressor
i in grado di agire direttamente sui mitocondri per innescare la morte delle cellule apoptotiche. È lipids able to act directly on mitochondria to trigger apoptotic cell death. It is interes
sante notare che sia ting that both VDAC1
che 2 possiedono, in una posizione simile, un and 2 own, in a similar position, a cysteine residu
o di cisteinae (Cys
127 in
el human VDAC1
umano e and Cys
138 in
el human VDAC2
umano) sotto forma di acido so) in the form of sulfonic
o con una forte carica acid with a strong negativ
a simile a quella del residuo acido glutammatoe charge resembling that of the glutamate acid residue [22]. In
vste
ce, l'ad, VDAC3 isoform
a VDAC3 non mostra alcun does not show any residu
o e homologo
aus to Cys
127/138 o
r Glu
73 embedded in
corporato nella porzione idrofobica dell' the hydrophobic moiety of the OMM.
VDAC1 present
a una tas
ca legante il c a cholesterol
o formata, i binding pocket formed, in human isoform
a umana, da residui di, by Ile
123,, Leu
144,, Tyr
146,, Ala
151e, and Val
171 [ 23].
Mitoc
hondrial
i formano porins form comple
ssi con altrexes with other protein
e, come ils, such as the adenine nucleotide translocase
dell'adenina (ANT),
la proteina trathe translocat
riceor protein (TSPO),
nota anche come recettore dellalso known as the peripheral-type benzodiazepine
di tipo perifericoreceptor (PBR),
HSP70 mitocmitochondrial
e e diverse HSP70, and several cytoskeletal protein
e citoscheletriche comes such as tubulin
a, actin
a, catena leggera della dineina e , dynein light chain, and gelsolin
a [11].
La protThe
ina tra translocat
riceor protein intera
gisce direttamente con tutte lects directly with all VDAC isoform
e VDACs. In partic
olare, l'ular, intera
zione traction between TSPO
eand VDAC1 contribu
isce a regolare l'tes to regulate the efficien
za dei meccanismi di controllo della cy of mitochondrial qualit
à mitocondriale e inibisce la mitofagiay control mechanisms and inhibits mitophagy, preven
endo l'ting ubiquitina
zione delletion of protein
e attraverso la s through downregulation
della via of the PINK1/Parkin
[24].pathway Il[24]. motivoThe GxxxG
simotif present
a sias both in VDAC
cheand in TSPO,
ed èand is necessar
io per questay for this intera
zionection [25].
InMo
ltrereover, VDAC1
eand TSPO, in associa
zione contion with StAR (steroidogenic acute regulatory protein), form
ano il trasdusoma, un complesso multi the transduceosome, a multi-protei
co coinvolto nel trasporto del cn complex involved in cholesterol
o. In una precedente ipotesi transport. In a former hypothesis, VDAC1
eand TSPO in OMM, ANT in IMM
e, and Cyclophilin D
nella matricin the mitoc
hondrial
e erano matrix were candidat
i a costituire il poro dies to constitute the permeability transi
zione di permeabilitàtion pore (PTP),
un poro ad altaa high condu
ttanza e non ctance and non-specific
o che consente il gonfiore pore that allows mitoc
hondrial
e e il rilascio di proteine swelling and release of apoptogenic
he. Più proteins. More recent
emente, è statoly, it was propos
to che il PTP potesse essere formato daed that PTP could be formed by dimer
i del complessos of the ATP s
intasiynthase complex [26].
Recent
i studi
hanno focalizzato l'attenzione sul ruolo delle proteinees have focused attention on the role of VDAC
nella disfunzioneproteins in mitoc
hondrial
e tipica di molte condizioni pat dysfunction typical of many pathologic
he tra cui ictusal conditions including stroke, canc
ro, encefalomiopatie mitocer, mitochondrial
i e invecchiamento, nonché disturbi encephalomyopathies, and aging, as well as neurodegenerativ
ie disorders [27][28][27,28].
L'Ma
nalisi della spetss spectrometr
ia di massa ha rivelato l'y analysis revealed the associa
zione tra VDAC e l'tion between VDACs and the ubiquitin
a ligas
ie Parkin. In presen
za dice of damaged mitoc
ondri danneggiati, come nel morbo di hondria, as in Parkinson
, La’s disease, Parkin
a viene fosforilata da is phosphorylated by PINK1
e diand conse
guenzaquently ubiquitina
letes protein
e che risiedono sull'OMM, prendendo di mira i mitocondri per la s that reside on the OMM, targeting the mitochondria for degrada
zionetion. Parkin
è una is a cytosolic protein
a citosolica ma trasloca nei but translocates to the mitoc
ondri per partecipare ai meccanismi di controllo della hondria to participate in mitochondrial qualit
à mitocondriale. Le proteine VDAC rappresentano un sito di attracco di Parkin sui mitocondri difettosi [29]y control mechanisms.
Moreover, VDAC
1 represents the main docking site at the mitochondrial level for misfolded and aggregated proteins, a common feature of neurodegenerative disorders known as proteinopathies, such as Alzheimer’s disease (AD), proteins represent a docking site of Parkin
son’s disease (PD), Creutzfeldt–Jacob disease (CJD), dementia with Lewy bodies (DLB), Huntington disease (HD), and amyotrophic lateral sclerosis (ALS) on defective mitochondria [29].
For example, in AD post-mortem brains, in neuroblastoma cells and in an AD mouse model, a direct association was demonstrated between VDAC1, specifically its N-terminal region, and hyper-phosphorylated Tau but also with amyloid beta (Aβ), both in its monomeric and oligomeric forms
[31]. These interactions can have a dramatic effect on mitochondrial functions in AD neuron because they block the PTP formation, disrupt the transport of mitochondrial proteins and metabolites, and impair gating, conductance, and physiological interactome of VDACs
[32].
In Parkinson’s disease, α-synuclein directly interacts with mitochondria, blocks VDAC1, and impairs metabolite fluxes leading, consequently, to an energetic crisis able to compromise cell viability
[33].
In ALS, several SOD1 mutants are able to bind VDAC1
[34]. This interaction impairs ATP/ADP exchange, VDAC1 conductance and mitochondrial membrane potential. Recently, the competition between SOD1G93A and HK1 was demonstrated in binding VDAC1, in NSC34 motor-neuron cell lines
[35].
In literature, the role of VDAC1 in neurodegeneration is rather well known; however, the involvement of the other two isoforms in these pathways remains poorly defined. This is likely associated with the relative abundance of VDAC1 compared to other isoforms which are more difficult to isolate in pure form.
Recent studies demonstrated that Cytoskeleton-associated protein 4 (CKAP4), a palmitoylated type II transmembrane protein localized to the endoplasmic reticulum (ER), regulates mitochondrial functions through an interaction with VDAC2 at ER-mitochondria contact sites
[36].
VDAC2 binds inositol trisphosphate receptors (IP3R) and regulates the release of Ca
2+ from the ER. In addition, several other interaction partners have been reported for VDAC2 isoform, which imply its effect in multiple cellular functions. Specifically, VDAC2 has been linked to many cellular proteins, including apoptotic factors as Bak and Bax, StAR, Metaxin2, eNOS (nitric oxide synthesize), GSK3β, tubulin, and Mcl1
[19]. In addition, VDAC2 and RACK1 (receptor of activated protein kinase C1) function as receptors for lymphocystis disease virus (LCDV) and for bursal disease virus in host cells
[37].
VDAC2 together with VDAC3 binds Erastin, the activator of ferroptosis, a new pathway that regulates cell death characterized by the iron-dependent accumulation of lipid hydroperoxides. Interaction between VDAC2/3 and Erastin results in degradation of the channels following activation of ubiquitin protein ligase Nedd4
[38].
Finally, the VDAC3 isoform is associated with cytosolic proteins as tubulins and cytoskeletal proteins, stress sensors, chaperones, and proteasome components, redox-mediating enzymes such as protein disulfide isomerase
[39].
2. Proteomics of VDAC Isoforms
2.1. Sample Preparation
Sample preparation has a profound effect on the final results of a proteomic workflow. Protein extraction methods and protein separation techniques should provide an unbiased and reliable map representative of all proteins present in a specific sample. The different extraction and fractionation approaches are based on proteins physicochemical and structural characteristics, such as molecular weight, solubility, hydrophobicity, and isoelectric point. A specific protocol has to be optimized for each particular sample, to maximize protein recovery and minimize the possible proteolysis and amino acid modifications. For these reasons, there is no universal extraction protocol and not a unique buffer composition. Regarding the extraction method, the different strategies available need to be compatible with both the amount of the processed material and the subsequent analytical approach (i.e., separation or MS).
The structural characterization of VDACs presents challenging issues due to their very high hydrophobicity, low solubility, and the impossibility to separate them from other mitochondrial proteins of similar hydrophobicity and to easily isolate each single isoform. In fact, isolation of VDACs has been possible exclusively for plant VDAC isoforms by chromatofocusing, thanks to the absence of phosphorylation sites in their structure
[40]. Consequently, it is necessary to analyze them as components of a relatively complex mixture.
A bottom-up proteomic approach was used to investigate the VDAC3 from rat liver mitochondria (rVDAC3)
[41]. According with a standard procedure
[42], mitochondria were extracted and lysed with a buffer containing 3% Triton X-100 at pH 7.0. The VDAC proteins were partially purified by hydroxyapatite (HTP) chromatography, which allows to obtain a VDACs enriched fraction which comprises also other mitochondria hydrophobic proteins. After precipitation with cold acetone, the protein pellet was solubilized in SDS buffer and loaded on a 17% polyacrylamide gel (1D-SDS-PAGE). The bands in the range 30–35 kDa were manually excised from the gel, cut in small pieces, and subjected to reduction with DTT and alkylation by addition of IAA. Finally, the reduced and carboxyamidomethylated proteins were in gel-digested using trypsin and chymotrypsin, and the resulting peptide mixtures were analyzed by nUHPLC/HRMS
[41]. MS data showed that rVDAC3 was found in the whole range 30–35 kDa, together with other proteins, mainly VDAC1, VDAC2, and several other mitochondrial proteins. The reason for VDAC3 electrophoretic heterogeneity probably stems from (i) the different pattern of cysteine oxidations that can modify the protein mobility; (ii) the different amount and quality of cysteine oxidations in various molecules (“redox isomers”).
The gel-digestion procedure shows some disadvantages: (i) larger peptides can get trapped between the gel meshes and lost during the extraction phase of the peptides from the gel; (ii) the electrophoretic procedure itself could damage the samples and alter the redox state of the sulfur amino acids (due to possible over heating generated by the applied voltage and to the presence of residual quantities of the catalysts used for the polyacrylamide polymerization). Furthermore, electrophoresis requires a relatively high amount of sample and the utilization of dyes and detergents. These last molecules could interfere with subsequent MS analyses because these compounds are difficult to eliminate from the sample.
2-DE could potentially represent a useful alternative to 1-DE to improve the separation of VDAC isoforms, but its utilization presents other problems. Actually, this kind of proteins has been under-represented in 2-DE gels due to difficulties in extracting and solubilizing them in the isoelectric focusing sample buffer. In fact, the most effective solubilizing agent for highly hydrophobic membrane proteins is SDS, but this detergent is incompatible with 2-DE. In addition to the difficulties in entering IPG (immobilized pH gradient) gels, membrane proteins tend to precipitate at their isoelectric point during IEF. Furthermore, their tendency to absorb the IPG matrix prevents their migration into the SDS-PAGE gel.
An improvement in the rVDAC3 mass spectrometric analysis was obtained following the introduction of a gel-free shotgun proteomic approach
[41]. According to this procedure, to avoid any possible artefact due to air exposure and manipulations, reduction/alkylation was carried out before VDACs purification from the mitochondria. Afterwards, all the proteins present in the HTP eluate, without previous electrophoretic separation, were purified from non-protein contaminating molecules with the PlusOne 2-D Clean-Up kit, and the desalted protein pellet was then re-dissolved in ammonium bicarbonate containing RapiGest SF to improve the solubility. In fact, this surfactant makes the proteins more susceptible to enzymatic cleavage without modifying the sample or inhibiting endoprotease activity. Furthermore, the RapiGest SF is compatible with enzymes such as trypsin or chymotrypsin and does not influence subsequent MS analysis because it can be easily removed in acidic conditions.
Separate aliquots of reduced and alkylated proteins were then subjected to digestion with modified porcine trypsin and chymotrypsin. In this experiment, every protein in the HTP eluate was digested, producing a very complex peptide mixture, which was finally analyzed by nUHPLC/HR nESI-MS/MS.
The new “in solution-digestion” protocol associated with nUHPLC/HR ESI-MS/MS allowed to extend the coverage of the rat and human VDACs sequences with respect to that obtained with the previous procedure
[43], so that it was possible to completely cover the rat and human VDAC1 sequences and almost completely the rat and human VDAC2 and VDAC3 sequences
[22][41][44]. It should be noted that the short regions not identified in VDAC2 and VDAC3 correspond to small tryptic or chymotryptic peptides or even to single amino acids, which cannot be detected in LC/MS analysis.
Moreover, by means of this new procedure a detailed characterization of PTMs of the three VDACs was obtained (see next paragraphs).
2.2. Mass Spectrometry Analysis of Post-Translational Modifications
The mammalian proteome is vastly more complex than the related genome. The reasons for this difference reside both in the molecular mechanisms that allow a single gene to encode for multiple proteins (genomic recombination, transcription initiation at alternative promoters, differential transcription termination, and alternative splicing of the transcript) and in the post-translational modifications (PTMs) which represent a wide range of chemical changes that proteins can undergo after synthesis. They include the specific cleavage of protein precursors, the covalent addition or removal of low-molecular weight groups (i.e., acetylation, glycosylation, hydroxylation, phosphorylation, ubiquitination) and the formation of disulfide bonds or other redox modifications
[45][46][47].
PTMs play crucial roles in cell biology since they can change protein physical or chemical properties, activity, localization, and/or stability. Traditionally, PTMs have been identified by Edman degradation, amino acid analysis, isotopic labeling, or immunochemistry. Within recent years, MS has proven to be extremely useful in PTM discovery. Post-translationally modified amino acids always have a different molecular mass than the original, unmodified residues and this mass increment or deficit is usually the basis for the detection and characterization of PTM by MS (commonly by LC-ESI-MS/MS).
MS has several advantages for characterization of PTMs, including (i) very high sensitivity; (ii) discovery of novel PTMs; (iii) ability to identify PTMs and the modified sites, even in complex protein mixtures; and (iv) ability to quantify the relative changes in PTM occupancy at distinct sites. None of the other techniques provide all these features, so the greater majority of the known PTMs have been described by MS
[48].
To improve sensibility, several methods have been developed to enrich the samples in proteins or peptides with specific PTMs prior to MS/MS analysis, such as anti-pY antibodies, IMAC (immobilized metal affinity chromatography) and TiO
2 for phosphorylation
[49][50], affinity capture with lectins for glycosylated proteins
[51], and resin coupled with anti-acetyl-lysine for acetylated proteins
[52]. Although, as previously described, isolation of single isoforms of VDACs cannot be obtained, application of combined HPLC and high-resolution ESI-MSMS analysis has resulted in the identification of several PTM in these proteins. In the following, a summary of the MS-based PTMs characterized in VDACs is reported and the respective biological significance discussed. These results are resumed in
Table 1 and
Figure 1.
Figure 1. Post-translational modifications of human (upper panel) and rattus (lower panel) VDAC isoforms. The image shows only the modified amino acids and their positions with respect to the cytosol, the outer mitochondrial membrane (OMM), and the intermembrane space (IMS). In the rVDAC1 Cys232 faces the aqueous inside of the pore; in the rVDAC3 Cys8 is located inside of the pore.
Table 1. Post-translational modifications in VDAC isoforms obtained using mass spectrometry. PTM type, mass shift (Da), source of the sample, modified residue, MS method and relative reference are reported. Studies are described by listing first author + year.
ISOFORM |
PTM Type |
ΔMass (Da) |
Source |
Residue |
Method |
Study |
VDAC1 |
Protein N-terminal acetylation |
42.0106 |
Rat liver |
Ala 2 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2018 |
HAP1 cells |
Ala 2 |
Pittalà et al., 2020 |
Acetylation |
42.0106 |
Mouse liver |
Lys 33, 41, 74, 234 |
nHPLC MS/MS in an LTQ MS |
Kim et al., 2006 |
Lys 41, 122, 132 |
nHPLC MS/MS in an LTQ 2D ion-trap MS |
Schwer et al., 2009 |
Mouse liver and heart |
Lys 237 |
UPLC Velos-FT MS |
Yang et al., 2011 |
Human liver |
Lys 28 |
LC/LC-MS/MS in an FTICR/MS |
Zhao et al., 2010 |
Oxidation |
15.9949 |
Rat liver |
Met 155 |
LC/LC-MS/MS in an FTICR/MS |
Guan et al., 2003 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2018 |
HAP1 cells |
Met 129, 155 |
Pittalà et al., 2020 |
Trioxidation |
47.9847 |
Rat liver |
Cys 127, 232 |
Saletti et al., 2018 |
HAP1 cells |
Cys 127 |
Pittalà et al., 2020 |
Phosphorylation |
79.9663 |
Rat liver |
Ser 12, 136 |
HPLC MS/MS in an LTQ MS |
Distler et al., 2007 |
Mouse liver |
Ser 117 |
nHPLC MS/MS in an LTQ MS |
Lee et al., 2007 |
HeLa cells |
Ser 101, 102, 104, Thr 107 |
nHPLC MS/MS in an LTQ-Orbitrap MS |
Olsen et al., 2006 |
Mouse brain |
Tyr 80, 208 |
LC-MS/MS in an LTQ FT MS |
Ballif et al., 2008 |
VDAC2 |
Protein N-terminal acetylation |
42.0106 |
Rat liver |
Ala 2 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2018 |
HAP1 cells |
Ala 2 |
Pittalà et al., 2020 |
Acetylation |
42.0106 |
Mouse liver |
Lys 32, 75 |
nHPLC MS/MS in an LTQ MS |
Kim et al., 2006 |
Lys 121 |
nHPLC MS/MS in an LTQ 2D ion-trap MS |
Schwer et al., 2009 |
Oxidation |
15.9949 |
Rat liver |
Met 167 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2018 |
HAP1 cells |
Met 12, 166 |
Pittalà et al., 2020 |
Trioxidation |
47.9847 |
Rat liver |
Cys 48, 77, 104, 211 |
Saletti et al., 2018 |
HAP1 cells |
Cys 47, 76, 103, 138, 210 |
Pittalà et al., 2020 |
Succination |
116.0110 |
Mouse brain |
Cys 48, 77 |
LC-nESI-MS/MS in an LTQ-Orbitrap MS |
Piroli et al., 2016 |
Rat liver |
Cys 48 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2018 |
Phosphorylation |
79.9663 |
HeLa cells |
Ser 115, Thr 118 |
nHPLC MS/MS in an LTQ-Orbitrap MS |
Olsen et al., 2006 |
Rat liver |
Thr 109 |
SCX-RP-MS/MS in an LTQ-Orbitrap MS |
Deng et al., 2010 |
Rat liver |
Tyr 237 |
HPLC MS/MS in an LTQ MS |
Distler et al., 2007 |
Mouse brain |
Tyr 207 |
LC-MS/MS in an LTQ FT MS |
Ballif et al., 2008 |
VDAC3 |
Protein N-terminal acetylation |
42.0106 |
Rat liver |
Cys 2 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2016 |
HAP1 cells |
Cys 2 |
Pittalà et al., 2020 |
Acetylation |
42.0106 |
Mouse liver |
Lys 20, 61, 226 |
nHPLC MS/MS in an LTQ MS |
Kim et al., 2006 |
Lys 63, 109 |
nHPLC MS/MS in an LTQ 2D ion-trap MS |
Schwer et al., 2009 |
Human liver |
Lys 28 |
LC/LC-MS/MS in an FTICR-MS |
Zhao et al., 2010 |
Oxidation |
15.9949 |
Rat liver |
Met 26, 155 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2016 |
HAP1 cells |
Met 26, 155, 226 |
Pittalà et al., 2020 |
Trioxidation |
47.9847 |
Rat liver |
Cys 36, 65, 165, 229 |
Saletti et al., 2016 |
HAP1 cells |
Cys 36, 65 |
Pittalà et al., 2020 |
Succination |
116.0110 |
Rat liver |
Cys 8, 36, 229 |
Saletti et al., 2018 |
Phosphorylation |
79.9663 |
Rat liver |
Ser 241, Thr 33 |
HPLC MS/MS in an LTQ MS |
Distler et al., 2007 |
Mouse brain |
Tyr 49 |
LC-MS/MS in an LTQ FT MS |
Ballif et al., 2008 |